News
Market and company headlines
MDTAll
Loading
00:00Oct 241 Story
05:00-00:00Oct 232 Stories
Medtronic (MDT) Stock Could Be A Bargain On Cash Flow
Medtronic has delivered a solid 51.6% share price gain over the past three years, while rolling out new cardiac devices and digital tools that could reshape how it earns and collects cash. With the stock around US$95.41, the open question is whether that price tag lines up with what the company’s cash flows can reasonably support. The 51.6% return over three years puts real weight on the issue of whether Medtronic’s current valuation can still be explained by its underlying cash...
Medtronic reports real-world findings for cardiac ablation systems
In the REAL PULSE prospective study, clinicians evaluated 1,160 AFib patients across 38 centres using the PulseSelect PFA system.
03:00-08:00Oct 222 Stories
Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).
Medtronic Announces Real-World Registry Results For Its Affera Mapping And Ablation System With The Sphere-9 Catheter And The PulseSelect Pulsed Field Ablation System; Analyses Report Strong Safety And Procedural Outcomes Across Atrial And Ventricular Arrhythmias
The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia
00:00Oct 211 Story
12:00-00:00Oct 202 Stories
Medtronic (MDT) Shares Moved, So What Is Driving Attention Now?
Medtronic (MDT) just expanded its leadership bench. The board appointed Michael Marinaro as President of Medtronic, adding oversight of Greater China to his existing Medical Surgical and global commercial responsibilities. Recent price action suggests cautious momentum for Medtronic. The 90-day share price return of 15.56% contrasts with a year to date share price decline of 1.48%, while the 3-year total shareholder return of 45.08% points to stronger gains for long term holders. Scan how...
Medtronic’s next-gen pacemaker portfolio secures CE mark
All five of the pacemakers within Medtronic’s Vitalis portfolio use conduction system pacing to directly stimulate the heart’s natural electrical wiring.
16:00Oct 191 Story
01:00Oct 171 Story
06:00-11:00Oct 162 Stories
MiniMed completes separation from Medtronic
Medtronic exchanged all of its remaining shares of the diabetes technology spinoff.
Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.
16:00-18:00Oct 152 Stories
Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?
Investors considering Medtronic (MDT) stock face an immediate concern: the shares returned 1.9% over the past year, trailing the 17.3% gain for the S&P 500. Yet Medtronic raised its outlook for the year in September, following higher fiscal first-quarter profit and sales. The company is also splitting off MiniMed Group, meaning the business you buy today is changing. So how much faster is Medtronic actually growing.
Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system and the Corsano™* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list.
10:00-13:00Oct 152 Stories
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic
MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the composition of its Board of Directors following the completion of the company's separation from Medtronic. This new Board
Medtronic Completes Separation of MiniMed Group, Inc.
Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).
16:00-22:00Oct 52 Stories
Is Medtronic (MDT) Undervalued Following Its Permanent CPT Code Win?
Medtronic (MDT) just picked up an important regulatory win, with the American Medical Association granting permanent Category I CPT codes for its Altaviva tibial neuromodulation implant and Symplicity Spyral renal denervation system. Medtronic shares closed at US$87.97, with a 1-day share price return of 1.84% following this regulatory update. However, the 30-day share price return is down 6.58% and the year-to-date move is down 8.41%, while the 3-year total shareholder return of 29.18%...
Medtronic (MDT) Outperforms Broader Market: What You Need to Know
Medtronic (MDT) concluded the recent trading session at $87.97, signifying a +1.84% move from its prior day's close.
09:00Oct 51 Story
00:00-08:00Oct 32 Stories
Medtronic’s 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?
Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why investors should own it.
Medtronic Has Been Boring Investors for Years. That Could Be Changing
Medtronic plc (NYSE:MDT) has been a bit of a slow burner. The company has a huge medical-device business and a dependable dividend, but growth has been difficult to find over the past few years. For investors, that has made Medtronic more of an income and stability play than a stock with much excitement around it. […]
15:00Oct 21 Story
12:00-17:00Oct 12 Stories
Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. T
Medtronic Receives American Medical Association Approval For Category I Current Procedural Terminology Codes For Two Its Technologies
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its
09:00-11:00Sep 303 Stories
IPO Education Foundation Names Medtronic's Dr. William J. Peine as 2026 Inventor of the Year
Intellectual Property Owners Education Foundation (IPOEF) announced that William J. Peine, Ph.D., Vice President of Research and Technology with the Surgical business of Medtronic, a global leader in healthcare technology, has been selected as the recipient of the 2026 Inventor of the Year Award for his contributions to patented innovations supporting the company's Hugo™ robotic-assisted surgery (RAS) system.
Medtronic Named to Fortune 2026 'Change the World' List for Touch Surgery(TM) Ecosystem and Healthy Neighbor
Company recognized for improving healthcare outcomes through technologyNORTHAMPTON, MA / ACCESS Newswire / September 30, 2026 / today announced it has been named to the prestigious FORTUNE 2026 ‘Change the World' list for its Touch Surgery™ ecosystem and Healthy Neighbor program through LABS. The annual list showcases companies working to combat global issues and drive positive social or environmental change.
04:00-06:00Sep 302 Stories
Medtronic Receives FDA Clearance, CE Mark For Its Affera Prism-2 Mapping Software, Also Receives CE Mark For PulseSelect ProxBox Adapter
Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug Administration (FDA)
TD Cowen Reiterates Buy on Medtronic, Maintains $110 Price Target
TD Cowen analyst Joshua Jennings reiterates Medtronic (NYSE:MDT) with a Buy and maintains $110 price target.
16:00Sep 291 Story
06:00Sep 281 Story
19:00Sep 271 Story
06:00-17:00Sep 242 Stories
Could Medtronic (MDT)’s $700 Million Robotics Bet Unlock its Next Growth Engine?
On September 1, Medtronic plc (NYSE:MDT) announced a $700 million strategic partnership with Hong Kong-based Cornerstone Robotics, securing rights to distribute Cornerstone’s Sentire surgical system in select market-approved regions outside the U.S. Medtronic will co-distribute Sentire alongside its proprietary Hugo robotic-assisted surgery system across Europe, China, and Singapore. The move allows Medtronic to offer tiered […]
Temperature Management Systems Market Forecasts Growth from $3.56B (2026) to $4.58B by 2031, Profiling 3M, Asahi-Kasei, GE Healthcare, Dragerwerk & Medtronic
The global temperature management systems market is projected to grow from USD 3.56 billion in 2026 to USD 4.58 billion by 2031, at a 5.2% CAGR. Growth is driven by rising surgical volumes, cardiovascular and neurological disorders, perioperative hypothermia prevention, and targeted temperature management in critical care. Patient warming systems and perioperative care led in 2025, while Asia Pacific is expected to grow fastest. Key players include Solventum, GE HealthCare, Dräger, Ecolab, Medtr
14:00-18:00Sep 232 Stories
Here's Why Medtronic (MDT) Fell More Than Broader Market
Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.
Medtronic (MDT): Q1 Beat Sparks Target Hikes, but Wall Street Splits on Re-Rating Case
Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story. Bull Case: Growth Is Broadening Mizuho […]
11:00Sep 231 Story
09:00-15:00Sep 222 Stories
Jim Cramer Called Medtronic a "Quandary." Here's Why He's Exactly Right.
Wall Street doesn't appear to be giving Medtronic credit for its improving results.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
06:00Sep 221 Story
04:00Sep 191 Story
10:00Sep 181 Story
03:00Aug 311 Story
02:00-09:00Aug 282 Stories
TD Cowen Maintains Buy on Medtronic, Raises Price Target to $110
TD Cowen analyst Joshua Jennings maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $100 to $110.
Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Medtronic plc (NYSE: MDT) will release Q1 earnings on Sept. 1. Analysts predict $1.39 EPS and $9.54B revenue. Stock fell 2.2% to $89.97 on Aug. 27.
18:00Aug 211 Story
11:00-17:00Aug 202 Stories
Medtronic announces cash dividend for second quarter of fiscal year 2027
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on October 16, 2026,
Electrosurgery Market to Grow from USD 8.60 Billion in 2026 to USD 11.59 Billion by 2031, at a CAGR of 6.2% – MarketsandMarkets™
Delray Beach, FL, Aug. 20, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global electrosurgery market to grow from USD 8.60 billion in 2026 to USD 11.59 billion by 2031, at a CAGR of 6.2% during the forecast period. Market growth is driven by the rising prevalence of chronic diseases, increasing surgical procedure volumes, growing adoption of minimally invasive surgeries, continuous technological advancements in electrosurgical systems, expanding healthcare infrastructure, and the inc
07:00-09:00Aug 202 Stories
Medtronic: Riding On Next-Gen Tech Medical Devices
Medtronic (MDT) Buy rating: cardiovascular device leadership, FY2026 revenue +8.4% and FY2027 7% growth guide.
Medtronic: Expecting Strong Revenue Growth In Fiscal Q1
Medtronic is reiterated as a Buy, with shares offering over 10% fundamental upside and attractive valuation metrics. Read more on MDT stock here.
18:00Aug 191 Story
05:00Aug 181 Story
06:00-08:00Aug 142 Stories
Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why itâs a Buyânew launches, insider buying, cost savings.
Medtronic (NYSE:MDT) Combines Dividend Quality with a Sustainable Yield
Medtronic (MDT) passes a quality dividend screen with a 7/10 rating, 3.35% yield, strong profitability, and a sustainable payout—though health and payout ratio merit caution.
08:00-10:00Aug 132 Stories
Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Medtronic (MDT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
FitLife Brands Inc. (FTLF) Beats Q2 Earnings and Revenue Estimates
FitLife Brands (FTLF) delivered earnings and revenue surprises of +11.11% and +0.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?